Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301938 | 0.88 | KLK7 (0.47) | KLK7PARP1JAK2JAK1STS | |
| SCHEMBL28549464 | 0.85 | PARP1 (0.46) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL14199452 | 0.83 | KLK7 (0.47) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL35210768 | 0.83 | TACR1 (0.44) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL35210684 | 0.82 | TACR1 (0.46) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL35211172 | 0.81 | KLK7 (0.42) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL8061462 | 0.81 | POLB (0.43) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL30181418 | 0.81 | POLB (0.43) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL28795618 | 0.81 | POLB (0.43) | NR1H2NR1H3KLK7PARP1AGTR2 | |
| SCHEMBL30207229 | 0.81 | POLB (0.43) | NR1H2NR1H3KLK7PARP1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | NR1H2 804/4885NR1H3 635/4885KLK7 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.